n
 
About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Wednesday, March 28th, 2018

The QualityStocks
Daily Stock List

graphic
graphic

GB Sciences, Inc. (GBLX)

Tip.us, Pumps and Dumps, Whisper from Wall Street, Wall St Report, CFN Media Group, AllPenny Stocks, Stockgoodies, SmallCapVoice, Cannabis Financial Network News, Money Morning, SeriousTraders, Otcstockexchange, PennyStockInformer, StocksToBuyNow, PennyStockLaboratory, Wall Street Resources and TradeThesePicks reported previously on GB Sciences, Inc. (GBLX), and we are highlighting the Company today, here at the QualityStocks Daily Newsletter.

GB Sciences, Inc. is a biopharmaceutical Research and Development (R&D) company. Its emphasis is on creating safe, standardized, pharmaceutical-grade, cannabinoid therapies, which target an assortment of medical conditions. GB Sciences’ R&D team is pursuing new formulations derived from specific strains of cannabis, creating patented formulations that will help patients. OTCQB-listed, GB Sciences has its head office in Las Vegas, Nevada.

The Company provides clean, reliable raw materials for numerous cannabis products and research initiatives. It is creating novel formulations and seeking patents for treatments that will directly assist patients.

The principal directive of GB Sciences since its inception has been the creation of a quality controlled cannabis cultivation and extraction facility to provide the compounds for formulating medicines to treat a broad variety of diseases.

GB Sciences has added its own medical-grade retail brand to its portfolio. This portfolio includes granted-medical and provisional-recreational use Nevada cultivation licenses and patent-pending medical formulations.

The Company announced in 2017 the initial harvest at its Cultivation Lab facility in Las Vegas. When fully operational, Cultivation Lab will contain 7,200 cannabis plants under 600 grow lights within its 28,000 ft. The expectation is that Cultivation Lab will generate roughly $10 million in yearly revenue.

GB Sciences and Cura Cannabis Solutions have executed a production agreement to produce high quality cannabis oils and related products using the GB Sciences production license operated by the GB Sciences' Cultivation Labs™. Cura Cannabis Solutions is the leading provider of premium cannabis oil and hemp oil to the legal domestic and international markets. It is known as the maker of the Select Oil and Select CBD group of products. The production agreement guarantees GB Sciences a set royalty on every gram produced and sold under the agreement.

In February, GB Sciences announced that it was issued its production license and now starts full production operations in the Las Vegas, Nevada facility. Production license partners include Relax With Happy™ (RWH), a new venture co-founded by veteran cannabis chef, Deliciously Dee™, and Cura Cannabis Solutions, maker of the best-selling cannabis brand on the West Coast, Select Oil.

Furthermore, in February, GB Sciences announced a new agreement with the Colorado Hemp Project. This agreement is to develop and cultivate boutique genetics and new strains of hemp that will provide the key ingredient in proprietary CBD formulations. GB Sciences will breed CBD into the genetics of the hemp plants and subsequently analyze and optimize results.

Today, GB Sciences announced that it signed a Letter of Intent (LOI) to purchase 100 percent of the ownership interests of NevadaPURE's Las Vegas operation for $28 million in cash and the assumption of about $5 million of outstanding liabilities.

The purchase is conditional on the completion of due diligence within roughly 30 days, negotiation of a final purchase agreement, as well as regulatory approval. Moreover, the deal provides GB Sciences with an additional three licenses from the State of Nevada. These include a cultivation license, a production license, and a dispensary license.

GB Sciences, Inc. (GBLX), closed Wednesday's trading session at $0.49, up 2.08%, on 655,273 volume with 319 trades. The average volume for the last 60 days is 1,907,102 and the stock's 52-week low/high is $0.21/$1.56.

Elite Pharmaceuticals, Inc. (ELTP)

SmallCapVoice, Top Stock Picks, PennyStocks24, TopPennyStockMovers, Marketbeat, Promotion Stock Secrets, Pennybuster, and Stock Analyzer reported on Elite Pharmaceuticals, Inc. (ELTP), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

OTCQB-listed, Elite Pharmaceuticals, Inc. develops oral sustained and controlled release products. A specialty pharmaceutical company, it is developing a pipeline of proprietary pharmacological abuse-deterrent opioid products and niche generic products. The Company specializes in oral sustained and controlled release drug products that have high barriers to entry. Elite Pharmaceuticals is headquartered in Northvale, New Jersey, where it operates a GMP and DEA registered facility for research, development, and manufacturing.

Elite’s lead pipeline products include abuse-deterrent opioids, which use the Company’s patented proprietary technology and a once-daily opioid. These products include sustained release oral formulations of opioids for the treatment of chronic pain.

Pertaining to Elite Pharmaceuticals’ proprietary abuse-deterrent technology, ART™, it is a multi-particulate capsule that contains an opioid agonist in addition to naltrexone, an opioid antagonist used primarily in the management of alcohol dependence and opioid dependence. When the product is taken as intended, the design of naltrexone is to pass through the body unreleased while the opioid agonist releases over time providing therapeutic pain relief for which it is prescribed.

Elite also provides contract manufacturing for Ascend Laboratories (a subsidiary of Alkem Laboratories Ltd.). Elite owns generic and Over-the Counter (OTC) products that have been licensed to TAGI Pharma, Epic Pharma, Dr. Reddy’s Laboratories, and Valeant Pharmaceuticals International.

Elite currently has nine commercial products selling, four products under review pending approval by the Food and Drug Administration (FDA), additional approved products pending manufacturing site transfer, and the NDA filing for SequestOx™.

This past January, Elite Pharmaceuticals announced that it received approval of its abbreviated new drug application (ANDA) from the FDA for Phendimetrazine Tartrate Tablets USP, 35 mg. The Phendimetrazine Tartrate approval is from an Elite ANDA filed about six years ago. Since the filing, the Company obtained a second approved Phendimetrazine Tartrate ANDA via Mikah Pharma.

Elite Pharmaceuticals has been selling the generic product for over five years. The Company is considering strategic options, including divestiture, for this newly approved ANDA.

In February, Elite Pharmaceuticals announced that it filed an Abbreviated New Drug Application (ANDA) with the FDA for a generic version of an immediate release CNS stimulant. The ANDA represents the first filing for a product co-developed with SunGen Pharma, LLC under the Development and License Agreement.

With this Agreement, the product will be owned jointly by Elite Pharmaceuticals and SunGen Pharma. Elite shall have the exclusive right to market and sell the product using its label. In addition, Elite will manufacture and package the product on a cost-plus basis.

Recently, Elite Pharmaceuticals announced results for Q3 of fiscal year 2018 ended December 31, 2017. Consolidated Revenues for Q3 were $2.5 million. This represents an increase of $0.2 million or roughly 9 percent from the comparable period the previous year. The increase in revenue is mainly due to growth across the Company’s generic product lines.

Elite Pharmaceuticals, Inc. (ELTP), closed Wednesday's trading session at $0.09976, down 1.23%, on 511,438 volume with 56 trades. The average volume for the last 60 days is 902,098 and the stock's 52-week low/high is $0.056/$0.2495.

Vilacto Bio, Inc. (VIBI)

OTC Markets and The Street reported on Vilacto Bio, Inc. (VIBI), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Vilacto Bio, Inc. is a biotechnology company listed on the OTCQB. It has developed the now fully patented Lactoactive® (Lactoactive molecule). In numerous studies, Lactoactive® has demonstrated above average effect treating conditions such as inflammatory diseases, diabetes, psoriasis, skin aging, and skin issues in different levels. At present the Company’s products are available on the market as Vilact®.

Founded in 2013, Vilacto Bio is headquartered in New York, New York. The Company previously went by the name Zlato, Inc. It changed its name to Vilacto Bio, Inc. on April 4, 2017. The Company’s European Headquarters are in Næstved, Denmark. Its Research and Development (R&D) operations are in Lithuania.

Vilacto Bio’s goal is to be the leading biotechnology company centered on commercializing unique pharmaceutical cosmeceutical products formulated or reformulated with Lactoactive® as nanoparticle according to its patented properties. The Company’s aim is to further develop its Lactoactive® molecule for increasing the quality of its retail and medical skin cream products, as well as licensing out its Lactoactive® molecule for the pharmaceutical industry.

Lactoactive® is highly refined colostrum, developed to provide first-rate results for people needing healing or relief from a range of skin issues. Lactoactive® is a refined processing of colostrum combined with hyaluronic acid. Proteins in Vilact® survive longer without being degraded by enzymes. This enables them to work longer in the skin.

Vilacto Bio has its Vilact Cuticle cream product, developed in cooperation with Danish podiatrists. Lactoactive, the ingredient molecule in Vilact Cuticle cream, works to help with skin challenges. Danish podiatrists have demonstrated its use with faster patient recovery.

This past January, Vilacto Bio announced that it started development of the Vilacto Bio Skincare Knowledge Center. This is an online resource that will gather skincare knowledge, science, insights and tips from scientists, dermatologists, podiatrists and other specialists around the world.

The tips and guides presented in the Vilacto Bio Knowledge Center will be shared with industry magazines internationally, and also with Vilacto customers. The expectation is that the Vilacto Bio Knowledge Center will enhance dialogue among specialists and consumers, improve outcomes, and drive higher traffic to Vilacto Bio’s commercial web portal.

Vilacto Bio, Inc. (VIBI), closed Wednesday's trading session at $0.34, down 2.58%, on 3,372 volume with 10 trades. The average volume for the last 60 days is 74,513 and the stock's 52-week low/high is $0.20/$2.13.

Wizard World, Inc. (WIZD)

Wall Street Resources and TopPennyStockMovers reported earlier on Wizard World, Inc. (WIZD), and we report on the Company as well, here at the QualityStocks Daily Newsletter.

Wizard World, Inc. is the foremost provider of multiple Comic Cons and pop culture conventions around the world. The Company produces Comic Cons (live multimedia conventions) and pop culture conventions. These celebrate pop-fi, pop culture, movies, television, cosplay, comics, graphic novels, toys, video gaming, sci-fi, gaming, original art, collectibles, contests and more. Wizard World has its headquarters in El Segundo, California. The Company’s shares trade on the OTC Bulletin Board (OTC BB).

Wizard World’s events frequently feature celebrities from movies and TV, artists and writers, and events such as premieres, gaming tournaments, panels, as well as costume contests. The Company has its ComicConBox™. This is a subscription-based premium monthly box service. It provides fans the opportunity to receive exclusive collectibles, toys, technology, games, licensed artwork, comics, apparel, Wizard World Comic Con tickets, VIP discounts and more, delivered to their doors.

The Company’s Comic Cons provide sales, marketing, promotions, public relations, advertising, and sponsorship opportunities for entertainment companies, toy companies, gaming companies, publishing companies, marketers, corporate sponsors, and retailers.

Wizard World Digital is the Company’s online publication. It covers new and upcoming products and talents in the pop culture world. Also, Wizard World has established a new SocialCon™ Operating Unit within Wizard World. SocialCon™ will produce a series of conventions. These will feature meet-and-greets, live performances, Q&A panels, autographs, photo opportunities and more with many of today’s most-followed social media influencers.

In addition, Wizard World has its CONtv. This is a subscription-based digital service. It brings fans their favorite films, TV series, comics, behind the scenes access to Wizard World Comic Cons, and more.

CONtv provides consumers access to thousands of hours of exclusive content highlighting an original slate of programming and a comprehensive digital catalog of over 1,200 titles. Furthermore, Wizard World has launched the new music concert series, and the Wizard World Store.

In September 2017, Wizard World announced its partnership with CNLive to distribute streamed content in the People's Republic of China (PRC). This partnership with CNLive, one of only seven entities licensed to distribute content over the internet in the PRC, provides Wizard World China, a wholly-owned subsidiary of Wizard World, a multi-year right and license to program a 24/7, advertising supported channel throughout all of mainland China. This includes Macao and Hong Kong.

Wizard World, Inc. (WIZD), closed Wednesday's trading session at $0.2486, up 0.24%, on 28,201 volume with 11 trades. The average volume for the last 60 days is 38,777 and the stock's 52-week low/high is $0.09/$0.35.

Mechanical Technology, Inc. (MKTY)

SmarTrend Newsletters, PinnacleDigest, StockOodles, and RedChip reported beforehand on Mechanical Technology, Inc. (MKTY), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Mechanical Technology, Inc. engages in the design, manufacture, and sale of test and measurement instruments and systems. These instruments and systems provide solutions for precision linear displacement, vibration measurement and balancing, and wafer inspection tools developed for markets that require the exacting measurement and control of products and processes in the development and implementation of automated manufacturing, assembly, and steady operation of complex machinery.

Established in 1961, Mechanical Technology is based in Albany, New York. The Company lists on the OTC Markets’ OTCQB.

Mechanical Technology conducts its work through its wholly-owned subsidiary, MTI Instruments, Inc. MTI Instruments’ products use a complete collection of technologies to solve complex, real world applications in many industries. These industries include manufacturing, electronics, semiconductor, solar, commercial and military aviation, automotive, and data storage.

MTI Instruments serves the industrial manufacturing/production markets, and the research, design and process development market. It also serves tensile stage systems for materials testing at academic and industrial research settings; and engine vibration analysis systems for military and commercial aircraft.

MTI Instruments has an acquisition based growth strategy. MTI is targeting for acquisition companies with $10 million to $30 million in annual revenues; and $2 million to $10 million in Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA).

Additionally, MTI is targeting for acquisition companies that manufacture precision test and measurement sensors, instruments, and systems used in automated manufacturing and assembly and consistent operation of complex machinery. Furthermore, MTI is targeting companies that focus on aerospace, semiconductor, electronics, automotive and/or general industrial sectors.

MTI Instruments’ test and measurement segment has three product groups. These are: Precision Instruments; Semiconductor and Solar Metrology Systems; and Balancing Systems. MTI is a worldwide supplier of precision linear displacement solutions, vibration measurement and system balancing solutions, and wafer inspection tools.

MTI Instruments has its 2D/3D line of laser scanners. The ProTrak™ 2D/3D line of products are advanced, high resolution, high speed profiling sensor product lines for use in industrial, robotic and manufacturing settings. The ProTrak series uses laser triangulation principles.

Mechanical Technology, Inc. (MKTY), closed Wednesday's trading session at $0.75, even for the day, on 2,000 volume with 1 trade. The average volume for the last 60 days is 4,691 and the stock's 52-week low/high is $0.65/$1.24.

Medibio Limited (MDBIF)

InvestorsHangout, OTC Markets, Stockhouse, 4-Traders, and AwesomePennyStocks reported on Medibio Limited (MDBIF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Medibio Limited is a digital health company founded in Australia and with offices in Melbourne (Vic), and Minneapolis, Minnesota. It has developed an objective testing system to assist in the screening, diagnosis, and treatment effectiveness of depression, chronic stress, and other mental health disorders. This test utilizes patented (and patent pending) circadian heart rate variability and cloud based proprietary algorithms to deliver a quantifiable measure to help in clinical diagnosis. Medibio’s shares trade on the OTC Markets Group’s OTCQB.

The Company is on course to commercialize its platform technology called the Digital Mental Health Platform. The foundation of this is on patented biomarkers from the autonomic nervous system. Medibio’s technology will provide a Diagnosis Aid to assist General Practioners (GPs) and mental health clinicians.

Pertaining to biomarker based objective diagnosis, a panel of circadian, sleep, and automatic system biomarkers enables automated, repeatable, and objective characterization of the impact of mental illness on the physiologic state. Medibio’s Digital Mental Health Platform is a device agnostic platform that can ingest data from manifold devices. It is highly scalable, low cost, and also easy to integrate.

The Company’s technology provides the first objective measure of stress. It provides a series of user and corporate dashboards for assessment and wellness partner interventions.

In October 2017, Medibio announce that it entered into an agreement with Otsuka Pharmaceutical Development & Commercialization, Inc. Medibio will apply its advanced proprietary analytic platform to Otsuka clinical data to characterize key circadian, autonomic, and sleep biomarkers related to serious mental illness. With this agreement, Medibio will receive payments for services provided.

This past December, Medibio announced the first prospective clinical trial with Mayo Clinic under a 5-year Master Clinical Trial Agreement signed in October 2017. The initial study undertakes the prospective diagnosis and longitudinal monitoring of unipolar and bipolar depression, along with the depressive subtypes (melancholic and atypical). The research study team will be led by Mark A. Frye, M.D., at Mayo Clinic’s Rochester campus.

Recently, Medibio announced that it signed a strategic partnership agreement with Striiv. The intention of this strategic partnership is to allow Striiv to integrate Medibio’s proprietary, personal mental health evaluation technology into its mobile app and assessment services.

Striiv has wrist-wearable devices. Therefore, this partnership provides the opportunity for Medibio’s technology to be used for longer term patient monitoring and management. Medibio anticipates completing integration with Striiv in this fiscal year.

This month, Medibio announced that it signed a term sheet to acquire Vital Conversations Pty Ltd. Vital provides evidenced based psychological health programs and a digital platform, which connects with Medibio’s technology to provide a complete set of products and solutions for the Corporate Wellness market.

This acquisition will create a new corporate health offering for Medibio. The new offering combines the psychological health content and digital platform of Vital Conversations with Medibio’s mental health technology platform and exclusive objective mental health measurement and monitoring capabilities. Vital Conversations is a foremost professional firm. It specializes in the facilitation of growth and optimum performance for individuals and organizations.

Medibio Limited (MDBIF), closed Wednesday's trading session at $0.1545, even for the day. The average volume for the last 60 days is 8,344 and the stock's 52-week low/high is $0.1545/$0.36.

Nautilus Minerals, Inc. (NUSMF)

OTC Markets, Stockhouse, Marketwired, MarketWatch, InvestorsHub, Barchart, Junior Mining Network, The Street, PennyStockTweets, YCharts, and Equities reported on Nautilus Minerals, Inc. (NUSMF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

OTCQB-listed, Nautilus Minerals, Inc. is the first company to explore the ocean floor for polymetallic seafloor massive sulphide deposits. The Company is developing a production system utilizing existing technologies adapted from the offshore oil and gas industry, dredging and mining industries to enable the extraction of these high grade Seafloor Massive Sulphide (SMS) systems on a commercial scale.

Nautilus Minerals has its corporate office in Toronto, Ontario. It has its Operations office in Brisbane, Australia. The Company also has offices in Kavieng, New Ireland, Papua New Guinea, and Nuku'alofa, Tonga, South Pacific.

Nautilus Minerals’ major shareholders include MB Holding Company LLC, an Oman based group with interests in mining, oil & gas that holds a 29.3 percent interest. Major shareholders also include Metalloinvest, the largest iron ore producer in Europe and the CIS that has an 18.5 percent holding (each on a non-diluted basis, excluding loan shares outstanding under the Company’s share loan plan).

A seafloor resource exploration company, Nautilus Minerals explores and develops the ocean floor for copper, gold, silver, and zinc seafloor massive sulphide deposits. In addition, it explores for manganese, nickel, copper, and cobalt nodule deposits.

Nautilus Minerals has its copper-gold project, Solwara 1. It is under development in the territorial waters of Papua New Guinea. Nautilus has been granted the Environment Permit and Mining Lease needed for resource development at this site.

In January of 2011, Nautilus Minerals was granted its first Mining Lease for Solwara 1. In December of 2009, the Environmental Permit for Solwara 1 was awarded.

The Solwara 1 deposit sits on the seafloor at a water depth of approximately 1600 meters. Solwara 1 contains a copper grade of roughly 7 percent. This compares with land-based copper mines, where the copper grade today averages 0.6 percent. Moreover, gold grades of significantly more than 20 g/tonne have been recorded in some intercepts at Solwara 1. The average grade is around 6 g/tonne.

In addition, Nautilus Minerals holds highly prospective exploration acreage in the western Pacific (granted and under application), and also in international waters in the Central Pacific.

Nautilus Minerals, Inc. (NUSMF), closed Wednesday's trading session at $0.175, up 0.29%, on 70,689 volume with 21 trades. The average volume for the last 60 days is 203,971 and the stock's 52-week low/high is $0.11/$0.3102.

Progressive Care, Inc. (RXMD)

OTC Markets and Investors Hangout reported on Progressive Care, Inc. (RXMD), and we report on the Company as well, here at the QualityStocks Daily Newsletter.

OTCQB-listed, Progressive Care, Inc., by way of its subsidiaries Smart Medical Alliance, Inc. and PharmCo, LLC, is a South Florida health services organization. The Company is moving ahead in its work to grow the Company by expanding its facility, adding new locations, acquiring operating pharmacies, and further developing its current business lines. Progressive Care is based in North Miami Beach, Florida.

Progressive Care is a provider of prescription pharmaceuticals, compounded medications, the sale of anti-retroviral medications, medication therapy management (MTM), and the supply of prescription medications to long term care facilities. In addition, the Company is a provider of administration and practice management, utilization management, quality assurance, EHR Implementation, billing and coding, and health practice risk management.

Progressive Care owns PharmCo LLC. PharmCo was created in 2005 as a Florida Limited Liability Corporation with the goal of becoming a premier pharmacy in the South Florida community. PharmCo has developed into a health services enterprise that focuses on the provision of prescription pharmaceuticals.

PharmCo’s compounding department specializes in formularies including non-narcotic topical pain creams, wound care creams, scar gels, and hormone replacement therapies. Furthermore, PharmCo offers EnovaRx, which are Food and Drug Administration (FDA) approved manufactured pain creams. These are readily available with a prescription.

PharmCo also prepares psoriasis creams, wellness vitamins, weight loss formulations and holistic capsules. These are 100 percent Kosher and Halal certified.

On September 1, 2016, Progressive Care opened Smart Medical Alliance, Inc. It opened Smart Medical to assist healthcare providers with navigating the complex risk management environment of their insurance network contracts. Smart Medical Alliance provides management and support services to doctors and administrators under capitated and fee-for-services insurance contracts.

This month, Progressive Care announced that it executed a Letter of Intent (LOI) to purchase a pharmacy in Palm Beach County. The Company signed an LOI on March 1, 2018 to purchase a pharmacy in Palm Beach County for $300,000. Progressive Care is starting the due diligence process with expected closing to take place in Q2 of 2018. The acquisition target is close to major highways in a 3,000 sq. ft facility. The operation has experienced staff, all applicable licenses, and commensurate PBM contracts as PharmCo, LLC, and a Parata PASS 500 unit dose packaging system.

Additionally, this month, Progressive Care announced strong sales for the month of February 2018. PharmCo, LLC filled more than 19,500 prescriptions during February, producing close to $1.45 million in Net Revenues. Prescriptions filled grew by 18 percent versus the same month the year prior.

The Company stated that Revenues remained flat year over year. Also, Progressive Care filled more than $450,000 worth of prescriptions (not included in Net Revenues) for 340B entities in February, generating fees to the pharmacy of roughly $20,000. This is almost a 200 percent increase over the same month the year prior.

Progressive Care, Inc. (RXMD), closed Wednesday's trading session at $0.139, down 20.57%, on 23,056,974 volume with 1,460 trades. The average volume for the last 60 days is 10,169,342 and the stock's 52-week low/high is $0.01/$0.2659.

Galway Metals, Inc. (GAYMF)

InvestorsHub, Dividend Investor, 4-Traders, Stockhouse, The Street, and GuruFocus reported on Galway Metals, Inc. (GAYMF), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

OTCQB-listed, Galway Metals, Inc. engages in the acquisition, exploration, and development of mineral resource properties. The Company has two mine exploration projects in Canada - Clarence Stream and Estrades. Galway Metals commenced trading on January 4, 2013, after the successful spinout to existing shareholders from Galway Resources following the completion of the US$340 million sale of that company. Galway Metals has its corporate office in Toronto, Ontario.

The Clarence Stream high-grade gold project is in the Province of New Brunswick. The Estrades Gold, Zinc, Copper and Silver VMS property is in the Province of Quebec.

Galway Metals has an Option Agreement to acquire a 100 percent undivided interest in the Clarence Stream gold project, located 70 kilometers (km) south-southwest of Fredericton in south-western New Brunswick. The Company’s land position consists of 60,465 hectares (149,412 acres) with 65 km of strike length (and a width of up to 28 km) along the Sawyer Brook Fault System. Galway released an updated NI 43-101 resource estimate prepared by SRK Consulting (U.S.) in September 2017. It included, for the first time, a pit constrained resource.

The Company has acquired an undivided 100 percent ownership interest in the former producing, high grade Estrades mine, related Newiska concessions, and neighboring Casa Berardi claims in western Quebec. These are situated roughly 95 km north of the town of La Sarre. The claims are mostly contiguous. They consist of 14,854 hectares, or 36,689 acres.

In February, Galway Metals announced that it purchased 14 additional claims next to its Estrades polymetallic VMS property in the northern Abitibi area of western Quebec. The claims are positioned along the Newiska felsic rhyolite horizon. This horizon has had intersections such as 1% copper plus 42 g/t silver over 9.4 meters (true width unknown).

The acquired claims are immediately south of the Estrades mine and existing resource. They include a regional cross fault, which may be an important mineralized feature in the camp.

The Company’s claims surround the new claims to the north, east and west. Therefore, this acquisition will allow for a full, uninterrupted gravity geophysical survey and other exploration activities over time, along the full 16 km extent of Galway’s Newiska horizon.

Galway Metals, Inc. (GAYMF), closed Wednesday's trading session at $0.188, down 1.05%, on 67,000 volume with 5 trades. The average volume for the last 60 days is 35,942 and the stock's 52-week low/high is $0.1649/$0.3603.

graphic

The QualityStocks
Company Corner

graphic
graphic

Petrogress, Inc. (PGAS)

The QualityStocks Daily Newsletter would like to spotlight Petrogress, Inc. (PGAS). Today, Petrogress, Inc. closed trading at $0.02095, up 4.75%, on 18,000 volume with 4 trades. The stock’s average daily volume over the past 60 days is 215,625, and its 52-week low/high is $0.0166/$0.072.

Petrogress, Inc. (OTC: PGAS) Petrogress, Inc.’s subsidiary, Petrogress Co., Ltd. (PGL), has entered into a Partnership Agreement with Platon Gas Oil Ghana.  PGL anticipates delivery of 3,000-5,000 metric tons of crude oil each month to Platon’s facilities for storage and processing into diverse petroleum products.

Petrogress, Inc. (PGAS) founded in 2009, owns and operates a fleet of tankers from its base in the historic Port of Piraeus, Greece, through a series of Marshall Islands subsidiaries. The company is an international merchant of petroleum products which includes reliably marketing and trading crude oil, distillates, and refined products off the coast of West Africa. The company also operates service and shipping facilities at the Port of Limassol in Cyprus and the Port of Tema, Greater Accra, in Ghana. It is actively seeking expansion opportunities, including in operating and developing natural gas production and transmission facilities along with LNG processing in the U.S., refinery operations in north and west Africa, and the transport and sales of LNG in Europe.

Petrogress has created a diversified revenue stream, giving it a significant advantage over similar companies working in the oil and gas shipping arena. A case in point is the recent formation of "PG Cypyard & Offshore Service Terminal Ltd. ("Cypyard"), through the company's wholly owned subsidiary, Petrogress Int'l, LLC. Cypyard is concluding negotiations for an operations and management agreement covering ports in Hellenic Cyprus, including the Port of Limassol, directly with the Cyprus Ports Authority. Current plans include a long-term lease with renewal options covering all in-place port facilities, including floating dock and dry dock areas, with cranes and scaffolding, construction and repair workshops and storage, and complete on-site administrative and office space.

"I think the opportunities there are great, and dealing directly with partners in government has numerous benefits," said Christos P. Traios, president of Petrogress Inc. in a news release announcing the venture. The recent appointment of two industry experts to the Petrogress Advisory Board is expected to help the company capitalize on future growth opportunities while simultaneously developing a comprehensive U.S. and international lobbying and government outreach program to facilitate business plans in the U.S., European Union and Africa.

Additional Petrogress Inc. subsidiaries are:

  • Petrogress Co. Ltd., an international merchant of petroleum products that combines regional market knowledge with over 20 years of excellent shipping experience.
  • Petrogress Co. Ltd., an international merchant of petroleum products that combines regional market knowledge with over 20 years of excellent shipping experience.
  • Petrogress Oil & Gas Energy Inc., which has expansion plans through a supply of liquified natural gas located in the oil fields of Texas with an eye toward exporting LNG to Mediterranean markets.

Petrogress continues to "adjust its sails" in order to meet new challenges. Opportunities include upstream oil resources and exploration, the addition of more product fleet carriers, downstream movement of petroleum products from refineries to finished sales, and sea transportation of liquified natural gas. A closely followed economist, Jim O'Neill, states that oil prices could spike more than 25% in the next year. O'Neill, now an economics professor at the University of Manchester, says the market is finally waking up to the fact that global economic growth is gaining momentum and likely expanding at 4 percent or higher. That means there will be more demand for oil, the article states, which translates into brighter days ahead for companies like Petrogress. Disclaimer

Petrogress, Inc. Company Blog

Petrogress, Inc. News:

Petrogress, Inc. (PGAS) Expanding Downstream Crude Oil Processing in Ghana with its New Feedstock Supply and Processing Agreement

NetworkNewsBreaks – Petrogress, Inc. (PGAS) Eyes Positive Future for Operations in West Africa

Petrogress, Inc. Announces Supply Agreement Expanding Operations into Ghana

Epazz, Inc. (EPAZ)

The QualityStocks Daily Newsletter would like to spotlight Epazz, Inc. (EPAZ). Today, Epazz, Inc. closed trading at $0.10, off by 0.40%, on 405,848 volume with 67 trades. The stock’s average daily volume over the past 60 days is 332,025, and its 52-week low/high is $0.0045/$0.52.

Epazz Inc. (OTC: EPAZ), a leading provider of blockchain cryptocurrency mobile apps and cloud-based business software solutions, announced today that the company has filed a provisional patent for its new blockchain electric health-care records portal technology.

Epazz, Inc. (EPAZ), is a leading provider of blockchain cryptocurrency mobile apps and cloud-based business software solutions that specializes in providing customized web applications to the corporate world, higher education institutions and the public sector. The company's strategic expansion into the investment fintech software space can be seen in the recent acquisition of the android app CryptoFolio, which securely tracks and manages Bitcoin and Altcoin portfolios. Epazz, Inc., which acquired the software rights, source code and user base of CryptoFolio, plans to add additional cryptocurrencies and languages to the app, along with an iOS version to attract more users.

Epazz also offers ZenaPay Bitcoin wallet, which has been downloaded more than 10,000 times since its launch on the Play Store. A subsidiary of Epazz, ZenaPay is a financial technology company that offers a unique, secure and reliable Bitcoin payment app, allowing consumers to acquire Bitcoin at the point-of-sale. The consumer can then use this digital currency to make a purchase with ease. The CryptoFolio business model provides free features to attract users and then allows users to purchase additional features from $1.99 to $5.99 each. CryptoFolio is a great add-on app for ZenaPay, and future versions of CryptoFolio will include an option to download ZenaPay.

"We are starting 2018 with ZenaPay on both major mobile apps' platforms," said Shaun Passley, PhD, CEO and founder of Epazz. "We are in the processing of developing new blockchain technology which will introduce an additional source of revenue streams for our company."

Epazz technology makes it easy to convert legacy systems into cloud business process software, for which the company then charges an annual subscription fee. Epazz has acquired 11 software companies that have converted or are in the process of converting their legacy software products to cloud software using Epazz technology. Epazz then markets the new cloud-based solutions to new and existing customers.

Epazz's unique BoxesOS™ applications can create virtual communities for enhanced communication, provide information and content for decision-making, and create a secure marketplace for any type of commerce. Epazz has also filed a provisional patent for its new blockchain smart legal contract technology that reduces fraud in business transactional contracts. The technology allows for a transactional contract to become a living contract that is tracked and traced; it also verifies that a section of terms within a contract are followed and that all parties of an agreement obey the terms of the contract.

"Blockchain-based technology is the future of the Internet," Passley said. "Epazz will add blockchain technology to all of our products in the coming months using our blockchain cloud platform, BoxesOS. The company has been working with customers to understand the best uses of blockchain, and we are excited about filing the first of many blockchain patents, with many more to come." Disclaimer

Epazz, Inc. Company Blog

Epazz, Inc. News:

Epazz Files Patent for Blockchain Electric Health-Care Records Portal Technology

Epazz, Inc. (EPAZ) Approaching Planned Debut of Cordtell in Second Half of 2018

Epazz, Inc. (OTC PINK: EPAZ) Featured on MoneyTV with Donald Baillargeon, 3/23

Choom Holdings Inc. (CSE: CHOO) (OTCQB: CHOOF)

The QualityStocks Daily Newsletter would like to spotlight Choom Holdings Inc. (CHOOF). Today, Choom Holdings Inc. closed trading at $0.6963, off by 2.95%, on 164,562 volume with 137 trades. The stock’s average daily volume over the past 60 days is 96,133, and its 52-week low/high is $0.125/$0.8612.

British Columbia-based cannabis cultivation firm Choom Holdings Inc. (CSE: CHOO) (OTCQB: CHOOF) this morning announced its entry into a letter of intent to acquire Flower Power Cannabis Pharms Inc., a retail brand experience cannabis company, as well as its wholly-owned subsidiary, High Way 10 Cannabis Pharms Inc. To view the full press release, visit: http://nnw.fm/W5UdI.

Choom Holdings Inc. (CSE: CHOO) (OTCQB: CHOOF) channels the laid-back spirit of Hawaii to the Okanagan region of British Columbia with a generous nod to the inspirational, yet unofficial, history of the 1970s "Choom Gang," a group of buddies in Honolulu (including former President Barack Obama) who knew how to relax with "choom," the local's term for marijuana. Choom's trademark slogans pivot off another unconventional phrase ("Say Hello to…"), bringing a heady dose of good times and good friends together as the company invites investors to "Say Hello to Choom™" as it lights up the adult recreational cannabis market in Canada.

Choom™ has been an ACMPR (Access to Cannabis for Medical Purposes Regulations) applicant since November 2013 in Vernon, B.C. The company's first application has received security clearance and is now in the detailed review stage. They also recently announced their second late-stage ACMPR application, which is in its confirmation of readiness stage. Cannabis Compliance Inc. has been retained to help expedite Choom's initial license applications to ensure the company's readiness for legalization of recreational marijuana in Canada mid-summer 2018.

True to the company's character, Choom™ is retrofitting two large facilities – No. 1 in Vernon, B.C., and No. 2 on Vancouver Island – to house its cannabis growing facilities. Phase 1 of the Vernon property will provide Choom™ with 6,800 square feet of growing space, capable of producing 660 kg/year of cannabis at an estimated revenue of $6.6 million, excluding oils. The company expects this facility to be completed by July 2018, the same month that Canada is expected to formally legalize recreational marijuana for adult use. A potential Phase 2, to be completed by the end of 2018, would add another 6,800 square feet for a total of 1,500 kg/year capacity, which would nearly double No. 1's revenue. A Level 9 vault is also planned with a storage capacity of 15,000 kg. While the No. 2 facility on Vancouver Island is smaller – 4,500 square feet – its retrofit is also slated to be completed by July 2018. Plans include doubling this space as well, which would add about $9 million in annual revenue, excluding cannabis oils.

Choom™ announced its retail dispensary strategy with the intention of establishing market leadership in reaching the Canadian cannabis consumer. The partner program is already in the retail space design stage as the company seeks to build a chain of branded retail cannabis dispensaries in jurisdictions in Canada where recreational cannabis is legal. Choom™ Stores will have a cool, modern layout and design created to emit an authentic "Aloha" vibe. Choom™ is all about producing high-grade cultivars and curating them for a bigger audience.

A savvy, experienced management team includes Chris Bogart, president and CEO; John Oh, R.P.I.C., Operations Manager; Robert Bayrack, Master Grower, S.P.I.C.; and Adrian Robinson, Strategic Advisor. Bogart has over two decades of international experience in capital markets and was a co-founder of InMed Pharmaceuticals and Magnum Uranium. He has structured complex equity financing transactions in the U.S., Europe and Canada. Bogart is joined on the Board of Directors by Kevin Pull, Stephen Tong and John Oh.

While the medical marijuana industry is expected to double by 2021 to 500,000 registered users, the true highlight of the recreational cannabis represents the key cultural shift set to launch in Canada. With an estimated $4.9B to $8.7B retail market coming, now is the right time for a Recreation Brand like Choom™ to be involved in this growing industry. Establishing and maintaining Choom™ premium brand loyalty is a key factor in the company's growth strategy. Get ready to "Say Hello" to opportunity, good times and good friends with Choom™. Disclaimer

Choom Holdings Inc. Company Blog

Choom Holdings Inc. News:

NetworkNewsBreaks – Choom Holdings Inc. (CSE: CHOO) (OTCQB: CHOOF) Enters LOI to Acquire Flower Power Cannabis Pharms Inc.

CannabisNewsBreaks – Choom Holdings Inc. (CSE: CHOO) (OTCQB: CHOOF) Prepares to Pounce on Canada’s Recreational Cannabis Market Following Upcoming Legalization

NetworkNewsAudio Announces Audio Press Release (APR) on Choom Holdings Inc. Pairing for Opportunity in Canada's Cannabis Market

PotNetwork Holdings Inc. (POTN)

The QualityStocks Daily Newsletter would like to spotlight PotNetwork Holdings Inc. (POTN). Today, PotNetwork Holdings Inc. closed trading at $0.339, off by 3.42%, on 2,535,126 volume with 664 trades. The stock’s average daily volume over the past 60 days is 13,445,305, and its 52-week low/high is $0.0006/$0.957.

PotNetwork Holding (OTC: POTN), through its wholly-owned subsidiary Diamond CBD Inc., this morning announced the release of a new B2C corporate video. To view the corporate video, visit: http://cnw.fm/S2kWG. To view the full press release, visit: http://cnw.fm/b3jXT.

PotNetwork Holdings Inc. (POTN), based in Fort Lauderdale, Florida, is a holding company. The company's First Capital Venture Co. subsidiary is the owner of Diamond CBD, Inc., a producer of widely-distributed CBD hemp extracts and the primary operating entity of PotNetwork Holdings.

Diamond CBD is made up of chemists and other scientists focused on developing and producing very high-quality CBD oil over a broad range of products, based upon a thorough understanding of the various natural molecules found in hemp and their particular properties. All products are made with federally legal cannabidiol (CBD), and are available in hundreds of flavors and sizes. The company emphasizes a dedication to 100% natural lab-tested CBD ingredients, with a carefully monitored process all the way from the source farm, through production, and final delivery to retail shelves.

PotNetwork, through Diamond CBD, delivers products to all 50 states, as well as internationally, and controls 15 CBD brands. The company lists the following product brands:

  • Diamond CBD Gummies - Diamond CBD branded edible gummies made from crystal isolate. Available in a variety of flavors and gummy styles, including rainbow bites, mini fruit, gummy worms, sour snakes, and more.
  • Chill Gummies - Chill gummies are more robust than its counterpart, the "Relax" gummy line. Chill Gummies are edible CBD gummies available in a wide variety of flavors, strengths, and styles including gummy bears, sour snakes, rainbow bites, watermelon slices, sour snakes, rainbow bites, peanut butter chocolate, ocean gummies, gummy worms, gummy rings and more.
  • CBD Liquid Gold - CBD Liquid Gold is derived from naturally grown industrial hemp plants, certified by USA labs and then carefully mixed with a patent-pending (non-PG) all-natural base formulation.
  • Blue CBD - Blue CBD Crystal Isolate is a high-end vapor liquid and oral drop infused with premium CBD rich hemp oil. CBD liquids are Premium Gold quality and test at a 7X higher concentration.
  • Relax Gummies - Relax Gummies give a lighter effect of CBD with some natural flavors in comparison to its counterpart Chill Gummies. Relax Gummies are perfect for anyone with a sweet tooth that's looking for a lighter effect without sacrificing quality or taste.
  • Premium Hemp Liquid Pet - CBD For Pets is a new and refreshing product from Diamond CBD for all the millions of pets out there. It is an organic product and also has unique flavors in it.
  • CBD Re-Leaf - Disposable, long-lasting, and ready to Use CBD Re-leaf vaping pens available in a variety of flavors. Easily take CBD anywhere on the go.
  • Relax Extreme CBD - Relax Extreme CBD Oil provides a high-quality, high-strength dose of CBD through oral drops. It is very easy to use and works instantly. Simply place a drop under the tongue. Available in various strengths.
  • CBD Double Shot - CBD Double Shots are specifically designed for one-time use. Easily squeeze the package in your mouth and swallow; it's that simple. Take it anywhere you go. Relaxation is now conveniently in your pocket. Drinkable CBD shots provide a quick boost of relaxation on the go. Available in various flavors.
  • Chill Pill - CBD infused capsules available in various strengths. Relax, take a Chill Pill.

Over 1.2 million people currently use cannabis, including CBD products, for medical application, including cancer, epilepsy, and depression. By sourcing hemp outside the U.S., the company avoids current federally-based legal problems involved in growing cannabis domestically. In the meantime, PotNetwork Holdings continues to target a large and rapidly developing cannabis market, expanding from $6.5 billion in 2016, to an expected $30 billion in 2021 (Forbes), and $50 billion in 2026 (Bloomberg). The cannabidiol market alone is projected to reach $2.1 billion in 2020, a 700% increase from 2015. PotNetwork Holdings Inc. plans to expand its subsidiaries as well as make strategic acquisitions. Disclaimer

PotNetwork Holdings Inc. Company Blog

PotNetwork Holdings Inc. News:

CannabisNewsBreaks – PotNetwork Holding, Inc. (POTN) Subsidiary Posts Corporate Video Highlighting Consumer Response to CBD Products

PotNetwork Holding Inc. Releases First Corporate Video Highlighting Its Success in the CBD Oil Industry

PotNetwork Holding, Inc. Creates New Market Opportunity for Domestic and International Pet Retailers with the Launch of Diamond CBD’s “MediPets” Product Line

Global Payout, Inc. (GOHE)

The QualityStocks Daily Newsletter would like to spotlight Global Payout, Inc. (GOHE). Today, Global Payout, Inc. closed trading at $0.0137, off by 4.86%, on 6,921,252 volume with 150 trades. The stock’s average daily volume over the past 60 days is 11,358,940, and its 52-week low/high is $0.0123/$0.16.

As blockchain becomes better established, companies across a wide range of industries are finding ways to benefit from the technology. Payment solutions company Global Payout, Inc. (GOHE) is providing blockchain services for logistics, payment, and high-risk businesses through a set of subsidiaries.

Global Payout, Inc. (GOHE) provides comprehensive payment solutions that can be fully customized for virtually any domestic and international organization distributing money worldwide. The company is committed to enabling global access to technology for optimizing financial transactions and delivering a global financial eco-system with top-tier banking institutions and the highest level financial technology partnerships.

Today, more than ever before, commercial enterprises and government institutions need powerful financial technology solutions that have the flexibility to deliver innovative customer centric services and drive operational efficiency gains throughout the organization. The Global Reserve Platform is Global Payout's fully configurable "banking-in-a-box" web-based platform that can fulfill the front-to-back office processing requirements of domestic, foreign exchange and international payment service providers. This platform is designed to improve work flow, operational efficiencies, and global financial management for enterprises operating across the globe.

The Global Reserve Platform can manage practically any financial product, including core and traditional banking products, online banking, card management, mobile wallets, merchant payment processing, biometric payments and authentication management, bill payments and P2P payments, international remittances, government benefits management, loans management, FOREX, and SWIFT / ACH / SEPA payments. Powered by the Global Reserve Administrative module, the platform can be customized for enterprises across a multitude of business sectors.

Investment in financial technology (FINTECH) companies has grown dramatically in recent years with the role of today's banks shrinking and demand for improved financial solutions continuing to rise. As the industry has continued to expand rapidly, Global Payout's management team has directed its focus on identifying the most promising market sectors with FINTECH needs. The four core areas selected are logistics, small and medium enterprises (SME), banking and travel.

In 2015, Global Payout introduced MoneyTrac Technology Inc. as a majority owned subsidiary to more effectively focus on the development of financial technologies that specifically address many of the challenges that enterprises in a variety of alternative and "high-risk" market sectors are faced with in processing financial transactions. Powered by Virtu Network Solutions, the MoneyTrac Technology platform is one the most configurable and intuitive financial technology platforms available to alternative and "high-risk" enterprises and provides them with solutions that effectively manages everything from pin debit and virtual currency, to compliance and cash flow logistics.

With the global economy constantly becoming more diversified and connected, Global Payout is well positioned with the technology software solutions its team has developed to address many different needs worldwide. Management has committed itself to exploring and identifying every avenue possible for further establishing itself as a recognized leader in FINTECH solutions. Disclaimer

Global Payout, Inc. Company Blog

Global Payout, Inc. News:

Blockchain Technology Brings Efficiency to Diverse Businesses

Joining Forces: MoneyTrac's Partners Sign JV to Supplement Services to the Cannabis Industry

NetworkNewsBreaks – Global Payout, Inc. (GOHE) Subsidiary Attends Cali-Baja Israel Mexico Innovation Expo

Liberty Leaf Holdings Ltd. (CSE: LIB) (OTCQB: LIBFF) (FSE: HN3P)

The QualityStocks Daily Newsletter would like to spotlight Liberty Leaf Holdings Ltd. (LIBFF). Today, Liberty Leaf Holdings Ltd. closed trading at $0.3251, off by 5.27%, on 21,416 volume with 18 trades. The stock’s average daily volume over the past 60 days is 123,427, and its 52-week low/high is $0.0091/$0.8074.

Liberty Leaf Holdings Ltd. (CSE: LIB) (OTCQB: LIBFF) (FSE: HN3P) is accelerating the potential of companies supplying the cannabis industry as it builds its vision of a ‘trellis of commerce’ that connects players in the legal markets for marijuana and related consumables.

Liberty Leaf Holdings Ltd. (CSE: LIB) (OTCQB: LIBFF), is a publicly traded Canadian-based company with strategic investments in businesses that are established, revenue- producing players in the medicinal and recreational cannabis market. Liberty Leaf’s focus is to build and support a diversified portfolio of cannabis-sector businesses, including those involved in the cultivation and processing of legal medicinal and recreational cannabis, value-added CBD/THC pet products, and supply-chain products for this dynamic and fast-growing sector. Liberty Leaf provides funding, management, HR resources and marketing expertise to help companies thrive and accelerate growth.

Liberty Leaf’s leading investments to date include:

  • North Road Ventures – An emerging end-to-end distributor of cultivated and manufactured cannabis products to licensed legal retailers. North Road has updated its application for an Access to Cannabis for Medical Purposes Regulations (ACMPR) license to be distribution/sales-focused, making the company unique in the crowded field of other cultivation-based applicants. This forward-thinking initiative will help fulfill the anticipated increase in Canada’s recreational cannabis space once legalization takes effect in mid-2018. The submission includes a boost in product-vault capacity that will result in a five-fold increase in products available for distribution. Cannabidiol (CBD)-oil products are expected to account for 50 percent or more of projected sales.
  • Just Kush Enterprises – Liberty Leaf holds a 60 percent interest in Just Kush, a cultivator of premium, proprietary cannabis strains selected for different levels of CBDs and THCs. Just Kush’s cultivation facility is located near Oliver, British Columbia, and it currently controls a facility which holds a Medical Marihuana Access Regulations (MMAR) license. The company is also a late-stage applicant for an ACMPR license (Access to Cannabis for Medical Purposes Regulations), which will enable Just Kush to produce cannabis for the medicinal and recreational market.

Liberty Leaf is also an active partner with the following companies:

  • ESEV R&D – A privately owned, medical marijuana research and development company based in New York with clinical laboratories located in Israel. ESEV R&D, in collaboration with a leading clinical research organization in Israel, has launched a one-of-a-kind service for North American medical cannabis companies to organize and oversee clinical trials seeking to demonstrate the efficacy of medical cannabis products for specific medical conditions. Liberty Leaf has a three-year collaborative agreement with ESEV. Under that agreement, ESEV is researching the efficacy of CBDs in pets, with the 1st formulation trial targeting canine osteoarthritis, a medical condition that includes: hip dysplasia; elbow dysplasia; and hind-knee, also known as stifle, degenerative joint disease (DJD).
  • Blox Labs Inc. – A boutique technology company focused on creating best-in-class smartphone apps and software solutions driven by emerging trends in blockchain, smart contracts and decentralized application technologies. Liberty Leaf and Blox Labs are developing “cannaBLOX,” a blockchain-based smart contract supply chain management platform for the legalized cannabis industry.

The company’s management team is led by President and Director William Rascan who has 25-plus years in the investment brokerage industry, most recently as a partner, senior investment advisor with Northern Securities. Rascan’s business experience ranges from active international trading clients to raising capital for junior mining companies on the TSX Venture Exchange.

Rascan is joined by CFO Jamie Robinson, a chartered accountant who specializes in accounting, auditing, and financial reporting under both IFRS and ASPE. Prior to joining Liberty Leaf, Robinson worked at Deloitte as a manager focused on publicly listed and private company audits, business review, performance enhancement engagements and restructuring proceedings.

Steven Feldman, who has more than 25 years of experience in the capital markets and was part of the original management team of SouthGobi Resources; and Doug Macdonell, a retired RCMP officer and recognized expert in the field of cannabis and cultivation, serve as company directors. Dr. Robert Jackman, who has worked closely with multiple clients in the medical cannabis and Natural and Non-prescription Health Products (NNHP) industries in North America, was recently appointed as scientific project manager/fulfillment.

Liberty Leaf’s advisory board includes international lawyer, writer and speaker Robert W.E. Laurie; Barinder Rasode, who currently serves as CEO of the National Institute for Cannabis Health & Education (NICHE); and Dr. Mary C. Fitzpatrick, B.S., D.V.M., whose primary focus is on helping companion animals live pain free in their senior years. Disclaimer

Liberty Leaf Holdings Ltd. Company Blog

Liberty Leaf Holdings Ltd. News:

Liberty Leaf Holdings Ltd. (CSE: LIB) (OTCQB: LIBFF) (FSE: HN3P) Building Seasoned Leadership Team for Growing Cannabis Portfolio

CannabisNewsBreaks – Liberty Leaf Holdings Ltd. (CSE: LIB) (OTCQB: LIBFF) (FSE: HN3P) Leverages Opportunity in Cannabis Industry through Strategic, Diversified Investments

Liberty Leaf Holdings Ltd. (CSE: LIB) (OTCQB: LIBFF) (FSE: HN3P) Readies Niche Products for Legal Cannabis Industry

Singlepoint, Inc. (SING)

The QualityStocks Daily Newsletter would like to spotlight Singlepoint, Inc. (SING). Today, Singlepoint, Inc. closed trading at $0.0349, off by 7.92%, on 16,530,686 volume with 783 trades. The stock’s average daily volume over the past 60 days is 8,185,370, and its 52-week low/high is $0.0132/$0.415.

SinglePoint Inc. (OTCQB: SING) joined by original Shark Tank member Kevin Harrington releases its fourth video of the year recapping key events and providing shareholders insight to the company's progress. Video: https://youtu.be/oTigJoaj6IA.

Singlepoint, Inc. (SING) has grown from a full-service mobile technology provider to a publicly-traded holding company. Through diversification into horizontal markets, SinglePoint is building its portfolio by acquiring an interest in undervalued subsidiaries, thereby providing a rich, diversified holding base.

SinglePoint's approach is to first research and identify acquisition opportunities in which it can take an active and influential role among existing leadership to provide enhanced strategy and direction. Target companies are undervalued, cash-flow positive, with high potential and verified assets. SinglePoint acquires and takes controlling interest of successful candidate companies.

SinglePoint recently signed a Letter of Intent to acquire an interest in Jacksam Corp., dba Convectium, a profitable California-based provider of equipment, branding, and packaging solutions for the cannabis industry. Convectium has developed the world's first cartridge and vape pen oil filling machine for wholesale distribution to dispensaries. The 710Shark and 710Seal systems can fill and package over 100 cartridges or disposable vape pens in 30 seconds and are sold to dispensaries through its EquipCanna.com brand. The company also operates a consumer brand that includes BlackoutX and HazeSticks and reaches customers in over 52 countries.

Additionally, SinglePoint has raised more than $300,000 and has signed a Letter of Intent to secure an additional $1 million in funding. The move provides management with ample capital to execute its business plan, while avoiding debt repayments that can eat into cash flow and reduce flexibility over time. It's also a rare development for a development-stage company in the cannabis industry.

Guided by a visionary leadership team with extensive experience in technology, engineering, marketing and raising capital, SinglePoint continues to explore high-potential acquisition opportunities to grow and diversify its current holding base. The company also plans to uplist to the OTCQB and become a fully reporting company during the current fiscal year.

The company has engaged Milost Advisors to pursue acquisitions and financing facilities toward funding acquisitions, as well as to provide working capital. Milost Advisors will assist SinglePoint in the acquisition of undervalued companies with annual revenues of at least $50 million, and has already identified potential acquisition targets for the company to consider. Disclaimer

Singlepoint, Inc. Company Blog

Singlepoint, Inc. News:

Video: Kevin Harrington Joins SinglePoint Management to Provide Update on Commercial Roll Out and Blockchain initiatives

SinglePoint Acquires ShieldSaver, Expanding Blockchain Technology Development into the Automotive Industry

NetworkNewsAudio Announces Audio Press Release (APR) on SinglePoint, Inc. Leveraging Creative Destruction with Blockchain

Lexaria Bioscience Corp. (CSE:LXX) (OTCQB:LXRP)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (LXRP). Today, Lexaria Bioscience Corp. closed trading at $1.05, off by 9.48%, on 16,530,686 volume with 783 trades. The stock’s average daily volume over the past 60 days is 8,185,370 and its 52-week low/high is $0.0132/$0.415.

CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, today announced that Lexaria Bioscience Corp. (CSE:LXX) (OTCQX:LXRP) has engaged CFN Media to conduct a 3-month investor and market visibility program to begin on March 28, 2018.

Lexaria Bioscience Corp. (LXRP) has developed and out-licenses its proprietary technology for improved taste, rapidity, and delivery of bioactive compounds, including cannabinoids. Though boasting a wide range of health benefits, cannabinoids are traditionally poorly absorbed by the body's gastrointestinal tract. To achieve higher effectiveness, consumers usually default to smoking. Lexaria provides a superior administration method by delivering hemp oil ingredients – or through locally licensed partners, cannabis oil ingredients – through a patented process within food products.

The key differentiator between Lexaria's products and others on the market is the company's disruptive technology proven to enhance the absorption of orally ingested cannabinoids while improving the "unusual" taste of cannabinoids and allowing for lower overall dosing with higher efficacy. Lexaria is primarily a B2B enterprise, and is in licensing discussions or has existing agreements with companies in Canada, the largest-market states in the USA, and internationally. Lexaria has also developed its own brands partly for demonstration purposes, utilizing its patented technology to infuse hemp oil ingredients within lipids in popular foods. These brands include ViPova™, Lexaria Energy Foods, and TurboCBD™.

In 2015, Lexaria commissioned an independent, third-party lab to test its technology under carefully monitored in vitro conditions. Results showed that the company's technological process and lipid formulation both improve intestinal absorption as much as 500%. Additional follow-up studies in human volunteers suggested that Lexaria's processed, lipid-infused tea may be more effective in an actual gastrointestinal system than in an in vitro simulation with results indicating as much as a 1,000% increase in overall absorption.

Lexaria also has an R&D partnership with the Canadian government's National Research Council. That R&D is expected to characterize molecular bond formation theorized to occur with Lexaria's unique technology between the lipid delivery agents and the bioactive substances it processes and combines. Results from this R&D are expected to support accelerating B2B relationships – not just in the cannabis industry, but also to support new B2B business relationships in the fields of vitamins, NSAIDs, and nicotine delivery. All of these sectors expected to offer additional future growth potential.

Aside from testing, a critical component of Lexaria Bioscience's business model is a strong intellectual property portfolio that utilizes the most commonly used food processing techniques. As of 2017, the company's patent portfolio includes 19 patent applications filed and pending in more than 40 countries around the world. The most recent patent applications expand Lexaria's lipophilic food and beverage composition claims to include the processing of cannabinoids, vitamins, NSAIDs and nicotine in many of the world's most commonly used food processing ingredients. Lexaria is expecting additional new patent awards both in the USA and internationally in 2017 and 2018.

Royalties play a vital role in Lexaria's revenue-generating business model. The company out-licenses its technology (royalty) to third party partners, and has several deals signed and/or pending. The company's growth initiatives are guided by a management team headed by CEO Chris Bunka, a serial entrepreneur who has raised more than $50 million in working capital for the companies he has led over the course of his career. He is supported by a team of professionals with extensive experience in pharmaceutical and bioscience sectors, invention, toxicology, consumer goods, and other relevant skillsets. Disclaimer

Lexaria Bioscience Corp. Blog

Lexaria Bioscience Corp. News:

Lexaria Biosciences Engages CFN Media to Broaden Investor Awareness -- CFN Media

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Helping Smokers Light Up Less

Lexaria Bioscience Corp. Receives New U.S. Patent Allowance for "Composition of Matter" Cannabinoid Delivery

Consorteum Holdings, Inc. (CSRH)

The QualityStocks Daily Newsletter would like to spotlight Consorteum Holdings, Inc. (CSRH). Today, Consorteum Holdings, Inc. closed trading at $0.0013, off by 27.78%, on 17,269,688 volume with 53 trades. The stock’s average daily volume over the past 60 days is 4,696,975, and its 52-week low/high is $0.0005/$0.0085.

Consorteum Holdings Inc. (OTC: CSRH), a software development company and mobile solutions provider, recently announced that its wholly owned subsidiary, 359 Mobile Inc., has inked an exclusive joint business agreement with DevLex Ltd. that will open new avenues of revenue for both companies (http://nnw.fm/J3cys).

Consorteum Holdings, Inc. (CSRH) is a software development and mobile solutions company focused on the delivery of digital offerings to mobile devices. The company provides mobile offerings, delivery of mobile content, mobile payments solutions and products through a mix of direct offerings, partnerships, license agreements and joint venture arrangements. A multi-year transition from a transaction management company focused on transaction processing solutions and products for the payment processing and financial transaction markets to multiple business verticals deepens the company's commitment to deliver innovating solutions to end users who are using smart handset devices in radical new ways.

Consorteum Holdings, utilizing its Universal Mobile Interface™ ("UMI") solution, offers opportunities in numerous markets with its capacity to support fully regulated, regionally compliant financial and social transactions via web and mobile. The company's UMI technology has the capacity to provide solutions in FinTech, data analytics, secure payment processing, compliance lead transaction management and various digital social event sectors. The UMI platform allows cross operating system development to support all mobile devices while addressing the complex and highly regulated needs of the mobile FinTech industry.

Led by the development team at Consorteum's wholly owned subsidiary 359 Mobile Inc., the Company has created an end-to-end FinTech solution utilizing the company's UMI technology platform. Current mobile application and transaction solutions are plagued by poor experiences. Because UMI's technology platform is designed to work across innovative payment, experience and product solutions, 359 Mobile believes there are both direct and partnership opportunities for the 359 Mobile UMI solution.

Consorteum's primary sales and marketing strategy is focused on enabling and delivering solutions to the global mobile FinTech market with an emphasis initially on mobile gaming. The trend towards increased mobile gambling supports the need for a mobile platform such as the UMI to meet existing and new compliance regulations for the online gambling industry. The online gambling market is projected to double to nearly $1 trillion by 2021, according to a study by Juniper Research, with the majority of growth in this sector attributed to mobile devices. Consorteum's management team believes there are fresh opportunities in this sector such as Mobile Marketing Services providing one-to-one marketing experiences for consumers; offering real-time services to Mobile Sports Book operators; and providing fixed odds betting solutions as well as social-based transactional solutions.

Consorteum's management team includes Chairman and CEO Craig A. Fielding, a co-founder of the company with extensive experience in technology, programming and large system building; and Chief Operating Officer Patrick Shuster, who has over 25 years of business experience in sales, engineering, operations and marketing for the telecommunications industry. They are joined by John Osborne, SVP of Technology of ThreeFiftyNine Inc., an innovator in embedded systems hardware and software design; Patrick Doran, SVP of business development and marketing with over 30 years of diversified experience in major corporations as well as early stage companies; and Glenn Charlesworth, VP of Accounting, a seasoned executive with a solid track record in financial reporting, strategic planning, general management and operations, finance, start-up situations, and cash flow challenged operations.

Consorteum Holdings is committed to bridging the mobile divide by providing mobile connectivity, secure transactional processing and social connectivity solutions for both cloud and hosted based offerings in multiple business sectors. Disclaimer

Consorteum Holdings, Inc. Company Blog

Consorteum Holdings, Inc. News:

Consorteum Holdings Inc. (CSRH) Inks Exclusive Alliance with Cutting Edge DevLex Predictive Analytics Platform

Consorteum Holdings, Inc. Executes Exclusive Distribution Contract with DevLex Ltd.

NetworkNewsBreaks – Consorteum Holdings, Inc. (CSRH) Targets Growing Mobile App Market Forecasted to Hit $110B by Year-end

graphic

Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters

graphic

1.

Fortune Stock Alerts
(AOXY) +76.92%

2.

QualityStocks
(RGNP) +31.25%

3.

StockMarketWatch
(ANW) +26.32%

graphic
By The Numbers Charts
QualitystockTwits

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors
















 

The QualityStocks By The Numbers Report

Click the chart below to see the full report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.

 

About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251